CORRESPONDENCE

Correspondence on the paper by Krauss–Etschmann S, Bush A, Bellusci S, et al.

We have read with interest the paper of Krauss–Etschmann et al. This is an important contribution to the current understanding of prenatal and early life events impacting chronic respiratory disease development and progression across the life cycle. A major challenge is to combine expertise in human conditions with complementary model systems. Better understanding of these links should allow novel prevention strategies to promote healthy ageing. In its important final message, the authors propose a roadmap for integrative research.

Since 2004, several initiatives funded under the EU Framework Programme for Research and Technological Development FP6-FP7 have attempted to identify, compare and evaluate pooling data from existing European birth cohorts with a major focus on respiratory and allergic diseases and their risk factors (GA²LEN: Global Allergy and European Network, FP6; ENRIECO: Environmental Health Risks in European Birth Cohorts, FP7; CHICOS: Developing a Child Cohort Research Strategy for Europe, FP7; and MeDALL: Mechanisms of the Development of ALLergy, FP7). McDALL emphasised the importance of multidisciplinary dialogue and integrative research to link molecular mechanisms with the population-based distribution of allergic diseases from birth to adolescence.

Developmental origins of ageing are in the EU research and political agenda. The Polish Priority of the EU Council (2011) promoted the recognition, prevention and management of chronic respiratory diseases in children to impact healthy ageing. The Cyprus Presidency of the EU Council (2012) identified research needs on birth cohorts to understand early determinants of chronic diseases. The previous initiatives are important in identifying research needs and strategies to be addressed in Horizon 2020 in Europe. Action Plan B3 (integrated care for chronic diseases) of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) includes health promotion and management with a life cycle perspective. To find novel health promotion strategies in chronic diseases, the results of FP6 and FP7 projects on prenatal and early life events, as well as epigenetics, will be discussed in a meeting organised in the fall of 2013 by the Region Languedoc Roussillon within the framework of Action Plan B3 of the EIP on AHA.

We fully support the road map of Krauss–Etschmann et al for a cross-disciplinary research. We also think that through collaborations with other EU projects, the target on chronic respiratory diseases of the COST action may be expanded to allergic diseases on one hand, and to all chronic diseases on the other.

J Bousquet,1,2 J M Anto,3,4,5,6 J Heinrich,7 T Kell,2 D S Postma,9,10 J Sunyer,3,4,5,6
1Department of Respiratory Diseases, University Hospital, Hôpital Arnaud de Villeneuve, Montpellier, France
2Respiratory and Environmental Epidemiology team, Inserm, CESP Centre for research in Epidemiology and Population Health, U1018, Villejuif, France
3Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
4IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
5CIBER Epidemiología y Salud Pública (CIBERESP), Spain
6Department of Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Barcelona, Spain
7Helmholtz Zentrum München, German Research Centre for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
8Institute of Social Medicine, Epidemiology and Health Economics, Charité—Universitätsmedizin Berlin, Berlin, Germany
9Department of Pulmonology, GRiac Research Institute, University Medical Center Groningen, Groningen, The Netherlands
10Department of Pulmonology, University of Groningen, Groningen, The Netherlands

Correspondence to Professor Jean Bousquet, CHRU Arnaud de Villeneuve, Service des Maladies Respiratoires, 34295 Montpellier Cedex 5, France; jean.bousquet@inserm.fr

Funding This correspondence was supported by the European Commission’s Seventh Framework Programme under grant agreement No 261357 (McDALL).

Contributors Dear Doctor Bush, We have read with great interest the recent paper of Krauss–Etschmann et al published in Thorax this month. We would like to make the following very positive comments for future collaboration. Best regards. JB.

Competing interests JB has received honoraria for participation in scientific and advisory boards, giving lectures, and press engagements from Actelion, Almirall, AstraZeneca, Chiesi, GlaxoSmithKine, Meda, Merck, Merck Sharpe & Dohme, Novartis, OM Pharma, Sanofi-Aventis, Schering Plough, Stallergènes, Takeda, Teva and Uriaich. TK has received research support from the European Union (EU) and DTG. DSP has received, for the University of Groningen, funding for research from Chiesi and AstraZeneca, and also for consultancies and/or lecturing at international meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed and TEVA.

Provenance and peer review Not commissioned; internally peer reviewed.


Received 14 March 2013
Accepted 15 March 2013

REFERENCES


Published Online First 12 April 2013

http://dx.doi.org/10.1136/thoraxjnl-2012-201902
Correspondence on the paper by Krauss–Etschmann S, Bush A, Bellusci S, et al.

J Bousquet, J M Anto, J Heinrich, T Keil, D S Postma and J Sunyer

Thorax 2013 68: 964 originally published online April 12, 2013
doi: 10.1136/thoraxjnl-2013-203563

Updated information and services can be found at:
http://thorax.bmj.com/content/68/10/964.1

These include:

References
This article cites 3 articles, 1 of which you can access for free at:
http://thorax.bmj.com/content/68/10/964.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/